key: cord-0736147-zq0lsyqd
authors: Wong, Grace Lai-Hung; Yip, Terry Cheuk-Fung; Wong, Vincent Wai-Sun; Tse, Yee-Kit; Hui, David Shu-Cheong; Lee, Shui-Shan; Yeoh, Eng-Kiong; Chan, Henry Lik-Yuen; Lui, Grace Chung-Yan
title: SARS-CoV-2 viral persistence based on cycle threshold value and liver injury in patients with COVID-19
date: 2021-04-23
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab205
sha: 0dc1ac1d7d4bdf4683fe63f9f068670eabf9fafb
doc_id: 736147
cord_uid: zq0lsyqd

BACKGROUND: Liver injury in patients with COVID-19 is common and prognostic. Direct viral tropism of SARS-CoV-2 for angiotensin-converting enzyme 2 receptors in hepatocytes may be one of the mechanisms of liver injury. We aimed to determine the role of viral persistence of SARS-CoV-2, based on cycle threshold (Ct) value, in liver injury in COVID-19. METHODS: This was a territory-wide retrospective cohort study of all public hospitals in Hong Kong. Laboratory-confirmed COVID-19 were identified. Serial liver biochemistries and Ct value of SARS-CoV-2 RNA were analyzed. RESULTS: We identified 7,622 COVID-19 patients (mean age 47 years, 48.2% male) diagnosed from 24 March to 1 January 2021 who had serial liver biochemistries and Ct values. 1,363 (17.9%) COVID-19 patients had ALT/AST elevations with two temporal patterns – early (within first 14 days from symptom onset) and late (after 14 days from symptom onset). COVID-19 patients with ALT/AST elevations had a lower Ct value at admission (23 vs. 25; P<0.001), day 5 (24 vs. 26; P<0.001) and day 20 (31 vs. 32; P<0.001) after admission, compared to those without ALT/AST elevations. COVID-19 patients with ALT/AST elevations had a longer duration from first positive to first negative RT-PCR of SARS-CoV-2 (13 vs. 9 days; P<0.001). ALT/AST elevation and presence of diabetes were the independent risk factors of viral persistence. CONCLUSIONS: Liver injury in COVID-19 is linked to a higher SARS-CoV-2 viral load during the early phase of infection, signifying a possible direct viral injury to liver. Prolonged viral persistence of SARS-CoV-2 is associated with liver injury.

A c c e p t e d M a n u s c r i p t 5 Abstract Background Liver injury in patients with COVID-19 is common and prognostic. Direct viral tropism of SARS-CoV-2 for angiotensin-converting enzyme 2 receptors in hepatocytes may be one of the mechanisms of liver injury. We aimed to determine the role of viral persistence of SARS-CoV-2, based on cycle threshold (Ct) value, in liver injury in COVID- 19 .

This was a territory-wide retrospective cohort study of all public hospitals in Hong Kong. Laboratoryconfirmed COVID-19 were identified. Serial liver biochemistries and Ct value of SARS-CoV-2 RNA were analyzed.

We identified 7,622 COVID-19 patients (mean age 47 years, 48.2% male) diagnosed from 24 March 

Liver injury in COVID-19 is linked to a higher SARS-CoV-2 viral load during the early phase of infection, signifying a possible direct viral injury to liver. Prolonged viral persistence of SARS-CoV-2 is associated with liver injury.

A c c e p t e d M a n u s c r i p t 6 Liver injury is frequently observed and prognostic in patients with COVID-19. [1] [2] [3] While this is likely a multifactorial phenomenon related to infection, hypoxia, co-medications etc., direct viral tropism for angiotensin-converting enzyme 2 (ACE2) receptors in the hepatocytes and cholangiocytes has been proven. 4, 5 Despite the relatively low percentage of hepatocytes expressing ACE2, receptor abundance may not be always consistent with organ symptoms, as transactivation of ACE2 may be triggered by inflammatory signals, such as type I interferon or IL-6 during SARS-CoV-2 infection. 6 Liver injury in COVID-19 patients remains a therapeutic challenge, as it is strongly associated with adverse clinical outcomes, 3, 7, 8 at the same time therapeutic options against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are potentially hepatotoxic. 9, 10 In view of the direct viral tropism in liver, the viral dynamics of SARS-CoV-2 infection may be linked to the trajectory of liver enzymes and risk of liver injury. In a recent modelling study, SARS-CoV-2 viral load increases rapidly in the initial stage and reaches the peak, followed by a plateau phase possibly generated by lymphocytes as a secondary target of infection. In the last stage of infection, SARS-CoV-2 viral load declines due to the emergence of adaptive immune responses.

When the initiation of seroconversion is late or slow, the model predicts viral rebound and prolonged viral persistence. 11 Hence viral persistence of SARS-CoV-2 and delayed seroconversion may reflect immunodeficiency as what has been observed in solid organ transplant recipients. 12, 13 The role of viral persistence of SARS-CoV-2 in disease severity in COVID-19 patients remains ambiguous and data are conflicting. Investigators in mainland China reported that patients who had viral persistence for longer than 16 days had more severe disease outcomes including extensive lung involvement and requirement of respiratory support. 14 Another small study in Hong Kong however did not demonstrate any association between prolonged persistence of SARS-CoV-2 (≥20 days after symptom onset) and severity of illness. 15 Prolonged persistence of SARS-CoV-2 for more than two weeks was observed in nearly one-fourth of asymptomatic COVID-19 patients. 16 Furthermore, no A c c e p t e d M a n u s c r i p t 7 studies specifically look into the relationship between the level and persistence of SARS-CoV-2 and liver injury. In the current study, we aimed to determine the role of viral persistence of SARS-CoV-2 on liver injury in COVID-19 patients.

A territory-wide retrospective cohort study was performed using data from the Clinical Data Analysis and Reporting System (CDARS) under the management of Hospital Authority, Hong Kong 17 .

CDARS is an electronic healthcare database that covers the patients' demographic, death, diagnoses, procedures, drug prescription and dispensing history, and laboratory results from all public hospitals and clinics in Hong Kong. 18 The Hospital Authority provides over 90% of healthcare service to the entire population. All suspected and confirmed cases of COVID-19 in Hong Kong are under the care of the Hospital Authority. We performed testing for SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) for both symptomatic patients presenting to outpatient clinics and hospitals, as well as asymptomatic close contacts of confirmed patients and inbound travellers. All data are deidentified in CDARS to ensure data privacy. Territory-wide studies on different infectious diseases including COVID-19 have previously been conducted using CDARS. 3, [19] [20] [21] [22] The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding was adopted in CDARS; its use in CDARS to identify medical conditions has validated to be 99% accurate when referenced to clinical, laboratory (including cycle threshold [Ct] value of SARS-CoV-2 RNA), imaging and endoscopy results from the electronic medical records. 23 The Centre for Health Protection (CHP), Department of Health of the Hong Kong Government provides daily update on individual laboratory-confirmed cases via its official website; data on COVID-19 onset date of all confirmed cases were obtained from CHP and linked to data in CDARS.

A c c e p t e d M a n u s c r i p t 8

We first identified consecutive laboratory-confirmed COVID-19 patients from 23 January 2020 to 1 January 2021 by virological results (Supplementary Table 1 

More than 99% of COVID-19 patients in Hong Kong were admitted to medical wards or intensive care units with isolation facilities. Initial investigations included a complete blood count (with a differential count), clotting profile (prothrombin time, activated partial-thromboplastin time, international normalized ratio [INR] ) and serum biochemical measurements (electrolytes, renal and liver biochemistries, C-reactive protein and lactate dehydrogenase, glucose and procalcitonin). 24 These laboratory assessments and chest radiography were performed regularly as clinically indicated.

A standardised real-time RT-PCR assay was used to detect a conserved region in the E gene of SARS-CoV and SARS-CoV-2 as well as other bat-associated SARS-related viruses (Sarbecovirus) as screening. 25 RT-PCR was positive if the Ct values of both the envelope (E) and RNA-dependent RNA polymerase (RdRp) genes of SARS-CoV-2 were less than 40. 26 Antibacterial therapy, using a beta-lactam-beta-lactamase inhibitor, or third generation cephalosporin with or without a macrolide or doxycycline, was initiated if bacterial infection was suspected or confirmed. 27 Supportive therapy, including supplemental oxygen, intravenous fluid, vasopressor support, mechanical ventilation, and renal replacement therapy, were given as appropriate. During the study period, patients were either recruited into clinical trials (NCT04276688, NCT04292730, NCT04292899), or given antiviral agents, including remdesivir, interferon beta-1b, ribavirin, or lopinavir-ritonavir, as indicated according to local interim guidelines. Systemic corticosteroids were given in patients requiring supplemental oxygen therapy. Patients were discharged when they improved clinically and with two consecutive clinical specimens tested negative for SARS-CoV-2.

Data were retrieved from CDARS in February 2021. Baseline date was defined as the date of diagnosis of COVID-19 by virological results. Demographic data including date of birth and gender were captured. Death dates were captured and ascertained using data from CDARS and Hong Kong Death Registry. Date of symptom onset was obtained from CHP. At baseline, haematological and virological parameters, liver and renal biochemistries, were collected. Thereafter, serial liver biochemistries, as well as SARS-CoV-2 viral assays and the Ct value for patients were collected until the last follow-up (Supplementary Table 1 ). We also retrieved data on other relevant diagnoses, procedures, admission to intensive care unit, concomitant drugs, laboratory parameters, and exposure to antivirals, antibiotics and antifungals, corticosteroids, interferon beta and immunoglobulin during the hospitalization (Supplementary Table 2 ).

Chronic hepatitis B and C were defined based on viral serology, use of antiviral treatment, and/or ICD-9-CM diagnosis codes. 20 Liver cirrhosis was identified by ICD-9-CM diagnosis codes for A c c e p t e d M a n u s c r i p t 10 cirrhosis and its related complications, and/or platelet counts <100x10 9 /L in a measurement at least 30 days before COVID-19 diagnosis (Supplementary Table 3 ). Hypertension was identified by any use of anti-hypertensive drugs and/or ICD-9-CM diagnosis codes (401-404); diabetes mellitus (DM) was defined by regular use of any anti-diabetic agents, and/or haemoglobin A 1c ≥6.5%, and/or fasting plasma glucose ≥7.0 mmol/L, and/or the ICD-9-CM diagnosis codes for DM (250). 28 Use of invasive mechanical ventilation was defined by ICD-9-CM procedure codes (96.04, 96.05, 96.7).

The primary outcome was ALT/aspartate aminotransferase (AST) elevation, which was defined as ALT and/or AST ≥2x the upper limit of normal (ULN). ULN of ALT and AST were defined according to the criteria of The Asian Pacific Association for the Study of the Liver (40 U/L for both genders). 29 Early and late ALT/AST elevation were defined as ALT/AST elevation that first analyzed by Chi-square test, or Fisher's exact tests for categorical parameters and Student's t test or Mann-Whitney U test for continuous parameters, as appropriate. Odds ratio (OR) and

adjusted ORs with 95% confidence interval (CI) of the lowest Ct value during SARS-CoV-2 infection on ALT/AST elevation were estimated by logistic regression. Linear regression was used to examine the relationship between ALT/AST elevation and time to first negative RT-PCR of SARS-CoV-2, and between ALT/AST elevation and the lowest Ct value during SARS-CoV-2 infection. We adjusted for the following covariates: age, gender, presence of liver cirrhosis, DM, hypertension, use of corticosteroids, remdesivir, and other antiviral agent included interferon beta, lopinavir-ritonavir, and/or ribavirin, and the lowest Ct value for linear regression between ALT/AST elevation and time to first negative SARS-CoV-2 RT-PCR; no patients were excluded in the analysis due to missing data. Backward stepwise selection was used to select significant covariates in multivariable models. All statistical tests were two-sided. Statistical significance was taken as P<0.05. Subgroup analyses were performed on patients with early or late ALT/AST elevation, compared to patients without any ALT/AST elevation.

We (Table 1) .

ALT/AST elevation occurred in 1,363 (17.9%) of COVID-19 patients (Table 1) (Table   2) .

We also observed two temporal patterns of ALT elevation ( Figure 3A ). 1,028/1,363 (75.4%) patients had onset of ALT elevation within the first 14 days after symptom onset; most of these patients had A c c e p t e d M a n u s c r i p t 13 their ALT peaked within one month from symptom onset; majority of them had received antiviral treatment for COVID-19 (68.5%) ( Figure 3B ). The other 335 (24.6%) patients had ALT elevation beyond the first 14 days after symptom onset; some of these patients had their ALT peaked beyond one month from symptom onset; and again majority of them had received antiviral treatment for COVID-19 (87.8%) ( Figure 3C ).

Patients who developed ALT/AST elevation had longer duration of viral persistence compared to those with persistently normal ALT/AST; they had a longer duration from first positive to first negative RT-PCR of SARS-CoV-2: 13 (8-18) versus 9 (5-13) days (P<0.001), a longer duration from admission to first negative RT-PCR of SARS-CoV-2: 13 (9-19) versus 10 (6-14) days (P<0.001), and a longer duration from symptom onset to first negative RT-PCR of SARS-CoV-2: 17 (12-22) versus 13 (9-17) days (P<0.001) ( Table 2) .

On univariate analysis by logistic regression, a lower trough Ct value was associated with ALT/AST elevation (OR 0.94, 95% CI 0.94-0.95, P<0.001). This remained as an independent factor on multivariable analysis (aOR 0.98, 95% CI 0.97-0.99, P<0.001). Other independent risk factors of ALT/AST elevation included use of corticosteroid, lopinavir-ritonavir (with or without ribavirin or interferon beta), male gender, and mechanical ventilation (Table 3) . Similar trend of trough Ct value associated with ALT/AST elevation was observed in early and late onset ALT/AST elevation ( Table   3 ).

Factors that might have contributed to early ALT/AST elevation (i.e. within 14 days after first symptom onset) include (on top of low trough Ct value) male gender, use of corticosteroids and other antiviral agents for COVID-19, and mechanical ventilation (Table 3) . Factors contributing to late A c c e p t e d M a n u s c r i p t 14 ALT/AST elevation (i.e. beyond 14 days after first symptom onset) include (on top of low trough Ct value) male gender, cirrhosis, diabetes mellitus, hypertension, use of corticosteroids and other antiviral agents for COVID-19, mechanical ventilation and renal replacement ( Table 3) .

On univariate analysis by linear regression, ALT/AST elevation, lower trough Ct value, older age, male gender, presence of liver cirrhosis, DM, hypertension, use of corticosteroid, remdesivir, and other antiviral agents for COVID-19 were associated with a longer duration from first positive to first negative RT-PCR of SARS-CoV-2 (Table 4 ). ALT/AST elevation remained as an independent risk factor on multivariable analysis (adjusted coefficient 1.02, 95% CI 0.62 -1.42, P<0.001); lower trough Ct value, presence of liver cirrhosis, DM, hypertension, use of corticosteroid, use of COVID-19 antiviral agents, and mechanical ventilation were also the independent risk factors. Use of remdesivir was associated with a shorter duration from first positive to first negative RT-PCR of SARS-CoV-2.

Similarly, on univariate analysis, ALT/AST elevation, lower trough Ct value, older age, male gender, presence of liver cirrhosis, DM, hypertension, use of corticosteroids, remdesivir, and other antiviral agents for COVID-19 were associated with a longer duration from hospital admission to first negative RT-PCR of SARS-CoV-2 (Table 4 ). Again, ALT/AST elevation, lower trough Ct value, presence of liver cirrhosis, DM, hypertension, use of corticosteroid and other antiviral agents, and mechanical ventilation were the independent risk factors on multivariable analysis; use of remdesivir was associated with a shorter duration from hospital admission to first negative RT-PCR of SARS-CoV-2.

A c c e p t e d M a n u s c r i p t 15

The independent risk factors for a longer duration from symptom onset to first negative RT-PCR of SARS-CoV-2 were ALT/AST elevation, lower trough Ct value, presence of liver cirrhosis, hypertension, use of corticosteroid, use of antiviral agents for COVID-19, and mechanical ventilation; use of remdesivir was associated with a shorter duration from symptom onset to first negative RT-PCR of SARS-CoV-2 (Table 4) .

ALT/AST elevation was independently associated with lower trough Ct value of RT-PCR of SARS-CoV-2 by linear regression (adjusted coefficient -0.76, 95% CI -1.14 --0.39, P<0.001). Among the COVID-19 therapeutic regimens, use of remdesivir and use of interferon beta (with or without lopinavir-ritonavir and/or ribavirin) combination therapy were associated with lower trough Ct value of RT-PCR of SARS-CoV-2 (Table 5 ). Whereas use of corticosteroid was not associated with that.

Among the patient characteristics, older age and presence of liver cirrhosis were also associated with lower trough Ct value of RT-PCR of SARS-CoV-2 (Table 5) . Liver injury in COVID-19 is important because it is not only common but also prognostically important. 3, 7, 30, 31 Yet the exact underlying mechanisms of liver injury in COVID-19 patients remain obscured. Patients who have a more severe form of COVID-19 are at a higher risk of liver injury; the risk could be two to three times higher than in those with mild-to-moderate COVID-19. 32 Yet, it is difficult to distinguish whether such liver injury is viral or immunologically driven. Corticosteroid therapy is a double-edged sword in COVID-19it has been shown to improve survival in hypoxic COVID-19 patients, whereas it may also prolonged SARS-CoV-2 persistence as demonstrated by us and other groups. 40 There was indeed a trend towards increased mortality in patients who did not require oxygen therapy treated with corticosteroid therapy. 41 In our previous study, corticosteroid therapy is one of the risk factors of liver injury. 3 This may be either due to more severe COVID-19, or possibly a longer duration of SARS-CoV-2 persistence.

The strength of our study includes a territory-wide cohort that covers 97.6% of all COVID-19 cases in Nonetheless, our study has a few limitations. First, we missed 696 out of 8,318 (8.4%) of COVID-19 patients because missing ALT or Ct values. However, we believe such relatively small proportion of missing COVID-19 subjects would not have major impact on the findings. Second, missing data of laboratory measurement might lead to biases as in other retrospective studies, though these biases can partially be compensated by our respectable cohort size. Some less common laboratory parameters, such as international normalized ratio, might not be checked for every single patient due to minor variations of clinical practice in different hospitals. Yet, missing data were rare for common laboratory parameters including ALT, total bilirubin and creatinine as those are regularly checked in our routine clinical practice. Missing anti-HCV was found in 44% of COVID-19 patients. As the prevalence of HCV in Hong Kong is low (0.3%), 42 the impact on our findings would be tiny. Third, ascertainment bias may affect the reliability of the study due to inaccurate entry of certain diagnosis codes for comorbidities, namely DM, hypertension, and liver cirrhosis. We minimized this bias by including diagnosis, laboratory as well as medication data for DM and hypertension. We have also measured serum platelet counts, and examined more definable ICD-9-CM codes for cirrhotic complications, which do not rely on a more accurate diagnosis of cirrhosis to identify the presence of cirrhosis. Patients who were first hospitalized because of COVID-19 may have some of their comorbidities missed. We believe those would be minor comorbidities as it is mandatory to enter diagnosis codes of the major comorbidities even they were hospitalized for COVID-19. Furthermore, any medical conditions warrant medical therapies, e.g. hypertension, diabetes mellitus, would have the medications dispensed during hospital stay and such information was also captured and used to define the relevant comorbidities. Lastly, there are yet more direct evidence, namely the PCR results or pathology of the liver, to further support the direct viral injury by SARS-CoV-2 to the liver in our ALT and/or AST elevation was defined by ALT and/or AST ≥2x upper limit of normal at baseline or during follow-up. The upper limit of normal of ALT and AST were 40 U/L.

Ct value was presented as median (interquartile range) and mean ± standard deviation. Duration was presented as median (interquartile range).

Negative RT-PCR of SARS-CoV-2 was indicated by a negative qualitative result or a quantitative Ct value ≥40.

* P values for multiple comparison were adjusted by Bonferroni correction. ALT = alanine aminotransferase; AST = aspartate aminotransferase; Ct = cycle threshold; RT-PCR = reverse transcription polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

M a n u s c r i p t 28 ALT and/or AST elevation was defined by ALT and/or AST ≥2x upper limit of normal at baseline or during follow-up. The upper limit of normal of ALT and AST were 40 U/L. * 1,028 patients with early ALT/AST elevation and 6,259 patients without any ALT/AST elevation were included. ^ 335 patients with late ALT/AST elevation and 6,259 patients without any ALT/AST elevation were included. Anti-HCV = antibody to hepatitis C virus; aOR = adjusted odds ratio; CI = confidence interval; Ct = cycle threshold; HBsAg = hepatitis B surface antigen; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

M a n u s c r i p t 30 A c c e p t e d M a n u s c r i p t 31 Positive anti-HCV -0.815 (-3.549 -1.918) 0.559 ALT/AST elevation was defined by ALT and/or AST ≥2x upper limit of normal at baseline or during follow-up. The upper limit of normal of ALT and AST were 40 U/L. ALT/AST elevation was forced into the multivariable model.

Use of antiviral agents included the use of lopinavir-ritonavir, ribavirin, and/or interferon beta.

Negative RT-PCR of SARS-CoV-2 was indicated by a negative qualitative result or a quantitative Ct value ≥40. ALT = alanine aminotransferase; AST = aspartate aminotransferase; CI = confidence interval; Ct = cycle threshold; RT-PCR = reverse transcription polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

A c c e p t e d M a n u s c r i p t 32 ALT and/or AST elevation was defined by ALT and/or AST ≥2x upper limit of normal at baseline or during follow-up. The upper limit of normal of ALT and AST were 40 U/L.

Other antiviral agents for COVID-19 included interferon beta, lopinavir-ritonavir, and/or ribavirin. ALT = alanine aminotransferase; AST = aspartate aminotransferase; CI = confidence interval; Ct = cycle threshold; RT-PCR = reverse transcription polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. 

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19

Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After

Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis

COVID-19-associated liver injury: from bedside to bench

Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China

Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large US Cohort

But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

Impact of Anti-Tumor Necrosis Factor and Thiopurine Medications on the Development of COVID-19 in Patients With Inflammatory Bowel Disease: A Nationwide Veterans Administration Cohort Study

Case 29-2020: A 66-Year-Old Man with Fever and Shortness of Breath after Liver Transplantation

COVID-19 in Liver Transplant Recipients: An Initial Experience From the US Epicenter

Clinical Characteristics, Hospitalization and Mortality Rates of COVID-19 Among Liver Transplant Patients in the United States: A Multi-Center Research Network Study

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Prolonged persistence of SARS-CoV-2 in the upper respiratory tract of asymptomatic infected individuals

Development Journey of Clinical Data Analysis and Reporting System (CDARS) in Hospital Authority of Hong Kong

Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China

Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From

Antiviral Therapy for Hepatitis B Prevents Liver Injury in Patients With Tuberculosis and Hepatitis B Coinfection

Collateral Effect of Coronavirus Disease 2019 Pandemic on Hospitalizations and Clinical Outcomes in Gastrointestinal and Liver Diseases: A Territory-wide Observational Study in Hong Kong

Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis

Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease

A Novel Coronavirus from Patients with Pneumonia in China

Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients

Reducing bacterial resistance with IMPACT -Interhospital Multidisciplinary Programme on Antimicrobial ChemoTherapy

American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1827 Patients in a Major U.S. Hospital Network

Elevated Liver Biochemistries in Hospitalized Chinese Patients with Severe COVID-19: Systematic Review and Meta-analysis

Characteristics of Liver Tests in COVID-19 Patients

Association of SARS-CoV-2 Genomic Load with COVID-19 Patient Outcomes

Repeat COVID-19 Molecular Testing: Correlation of SARS-CoV-2 Culture with Molecular Assays and Cycle Thresholds